Stakeholders Respond to the FDA’s Psychedelics Docket, Revealing Broad Support and Divisions Over Regulation, Therapy, and Trial Safeguards

An analysis of 610 submissions to the U.S. Food and Drug Administration’s psychedelics docket finds that stakeholders were broadly supportive of advancing psychedelic research and access, while divided over how regulation should work. Nearly 500 submissions were distinct, alongside almost 100 template-style comments and 14 duplicates. The review examines submitter types, positions on the FDA’s four topics, recurring themes, coordinated campaigns, and major fault lines, including the role of psychotherapy, product-specific rules, and clinical-trial safeguards. The analysis used AI to retrieve and categorize comments and identify themes, followed by human review. The docket also contained irrelevant or unusual submissions, highlighting limitations in the underlying public-comment record and the need for careful interpretation.